Data gathered: November 27
AI Stock Analysis - Salarius Pharmaceuticals (SLRX)
Analysis generated August 13, 2024. Powered by Chat GPT.
Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with cancer. The company's primary aim is to deliver treatments that address unmet medical needs, specifically in the treatment of rare and hard-to-treat cancers. Through their proprietary technologies and extensive research methodologies, Salarius aims to bring transformative therapies to market.
Stock Alerts - Salarius Pharmaceuticals (SLRX)
 |
Salarius Pharmaceuticals | November 25 Price is up by 5.1% in the last 24h. |
|
Salarius Pharmaceuticals | November 22 Price is down by -5.5% in the last 24h. |
|
Salarius Pharmaceuticals | November 21 Price is up by 5.7% in the last 24h. |
|
Salarius Pharmaceuticals | November 18 Price is up by 5.2% in the last 24h. |
Alternative Data for Salarius Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 90 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Employee Rating | 100 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 12,431 | Sign up | Sign up | Sign up |
| Twitter Mentions | 20 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
| Linkedin Employees | 12 | Sign up | Sign up | Sign up |
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need.
| Price | $1.45 |
| Target Price | Sign up |
| Volume | 30,100 |
| Market Cap | $2.2M |
| Year Range | $1.29 - $4.96 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
Warning: SLRX is at high risk of performing badlyOctober 31 - Seeking Alpha |
|
 |
SLRX stock touches 52-week low at $1.3 amid market challengesOctober 14 - Investing.com |
|
SLRX stock touches 52-week low at $1.34 amid market challengesOctober 4 - Investing.com |
 |
Salarius: Q3 Earnings SnapshotNovember 14 - Biztoc.com |
Biotech Alert: Searches spiking for these stocks todayOctober 17 - Thefly.com |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 870,000 | -870,000 | -970,000 | 0 | 0.000 |
| Q2 '24 | 0 | 1.3M | -1.3M | -1.4M | -1.5M | -2.370 |
| Q1 '24 | 0 | 1.5M | -1.5M | -1.7M | -1.8M | -0.410 |
| Q4 '23 | 18,000 | 910,000 | -910,000 | -880,000 | -970,000 | -0.220 |
| Q3 '23 | 0 | 1.5M | -1.5M | -2.4M | -2.5M | -0.650 |
Insider Transactions View All
| Lieber Jonathan I filed to buy 37,500 shares at $0.2. June 8 '22 |
| Burleson Tess filed to buy 32,050 shares at $0.2. June 8 '22 |
| McVicar William K. filed to buy 26,553 shares at $0.2. June 7 '22 |
| HANISH ARNOLD C filed to buy 46,350 shares at $0.2. June 6 '22 |
| Rosenblum Mark J filed to buy 148,319 shares at $0.2. May 31 '22 |
Similar companies
Read more about Salarius Pharmaceuticals (SLRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Salarius Pharmaceuticals?
The Market Cap of Salarius Pharmaceuticals is $2.2M.
What is the current stock price of Salarius Pharmaceuticals?
Currently, the price of one share of Salarius Pharmaceuticals stock is $1.45.
How can I analyze the SLRX stock price chart for investment decisions?
The SLRX stock price chart above provides a comprehensive visual representation of Salarius Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Salarius Pharmaceuticals shares. Our platform offers an up-to-date SLRX stock price chart, along with technical data analysis and alternative data insights.
Does SLRX offer dividends to its shareholders?
As of our latest update, Salarius Pharmaceuticals (SLRX) does not offer dividends to its shareholders. Investors interested in Salarius Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Salarius Pharmaceuticals?
Some of the similar stocks of Salarius Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.